NL-OMON26218已完成不适用
A Phase 3, Randomised, Open-Label, Comparator-Controlled, Parallel-Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta-Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c.
Eli Lilly and Company, Lilly Nederland BV0 个研究点目标入组 75 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with type 2 diabetes mellitus (m/f);
- •2. 30-70 years of age;
排除标准
- •1. Use of oral anti-diabetic therapy other than metformine.
- •2. Clinical significant history or presence of hepatic-, renal-, central nervous system-, gastrointestinal-, haematological- and pulmonary disease;
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, randomized, open label, comparator-controlled, parallel-group, multicentre study to compare the effects of exenatide and insulin glargine on beta cell function and cardiovascular risk markers in subjects with Type 2 diabetes treated with metformin who have not achieved target HbA1c - 114Type 2 diabetes mellitusEUCTR2004-000577-65-FIEli Lilly and Company75
尚未招募
3 期
Bomedemstat vs BAT for Essential Thrombocythemiaessential thrombocythemiaJPRN-jRCT2031230658Koh Yasuhiro17
进行中（未招募）
不适用
Study to investigate the safety and efficacy of tacrolimus in kidney transplant recipientsKidney transplant recipientsMedDRA version: 18.0Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865EUCTR2015-003288-12-Outside-EU/EEAFujisawa Healthcare, Inc.660
进行中（未招募）
不适用
A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMAFirst line therapy for surgically incurable advanced melanomaMedDRA version: 14.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-002827-15-ITPFIZER630
已完成
3 期
A clinical trial to study effectiveness and safety of two medications in patients suffering from dyslipidemia (abnormal lipid levels in blood)CTRI/2011/04/001689Cadila Healthcare Ltd200